Pressure Surface denied as duplicate or overlapping therapy by Blue Cross Blue Shield?
If two medications appear duplicative on paper but serve different clinical purposes (e.g., short-acting vs long-acting), the appeal needs to spell out the clinical rationale for both.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What Blue Cross Blue Shield typically requires
Blue Cross Blue Shield's specific coverage criteria for pressure surface are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.
The Blue Cross Blue Shield angle on Pressure Surface
## Why BCBS Denied a Pressure-Relieving Surface as Duplicate Therapy
A duplicate-therapy denial from Blue Cross Blue Shield (BCBS) for a pressure-relieving support surface (such as a specialized mattress, overlay, or cushion used for pressure injury prevention or treatment) typically occurs when the plan's records show another pressure-management device or supply is already authorized or on claim. This can also happen when a higher-specification surface is requested while a lower-specification one remains active. Duplicate-item denials are often administrative in origin — the plan's system is flagging an overlap that does not reflect your actual clinical situation — and they are regularly reversed when the clinical distinction is clearly documented.
## Why This Denial Is Appealable
For a duplicate-therapy determination to stand, BCBS must demonstrate that the already-covered item serves the same clinical function at the same level of need. If your condition has worsened, if the existing surface is no longer clinically adequate, or if the requested surface addresses a different wound site or severity level, the "duplicate" characterization is factually incorrect. Medicare criteria (if applicable) and the applicable BCBS medical policy both define tiered criteria for different surface specifications — your appeal should demonstrate which tier your current clinical status requires.
## Federal Appeal Framework
- Internal appeal (ACA §2719 / ERISA §503): You have the right to a full-and-fair internal review of any adverse benefit determination. The denial notice states your appeal deadline — preserve it.
- External review: If the internal appeal is denied, you may request independent IRO review at no cost, generally within four months of the final denial. Expedited review is available when delay would seriously jeopardize your health or ability to regain maximum function.
- Medicare Advantage note: If your BCBS plan is a Medicare Advantage product, CMS-specific appeal rights also apply, including the right to a Qualified Independent Contractor (QIC) review.
## Concrete Appeal Process and Timeline
1. Identify exactly which item BCBS claims duplicates the requested surface. 2. Have your prescriber or wound-care clinician document why the current item is clinically inadequate and why the requested surface is distinct and necessary. 3. Submit a formal internal appeal with all supporting documentation. 4. If denied, file for external IRO (or QIC, if Medicare Advantage) review within the stated window.
## Documentation to Gather
- Wound or skin-integrity assessment: Current clinical documentation of your wound stage, skin condition, or pressure-injury risk level — performed by a wound-care nurse, physician, or physical therapist — with dates.
- Inadequacy of existing surface: Notes explaining specifically why the item already on file does not meet your current clinical needs (e.g., worsened condition, different anatomical site, different required surface specification).
- Prescriber order and medical-necessity letter: A letter from your treating provider explaining the clinical distinction between the currently covered item and the requested surface, and why both cannot serve the same purpose.
- Prior treatment history: Documentation of any pressure injuries, skin breakdown events, or failed attempts with the current equipment, with dates and outcomes.
- BCBS medical policy: Obtain BCBS's published coverage policy for pressure-relieving surfaces; map your clinical documentation to each criterion.
## Criteria-Mapping Structure
For each BCBS coverage criterion cited in the denial:
| BCBS Coverage Criterion | Specific Clinical Evidence Meeting It | |---|---| | [Copy exact language from denial or BCBS policy] | [Wound assessment date/finding, prescriber note, or equipment history] |
A structured criteria map — with dates and clinical specifics for each requirement — is the most effective format for reversing a duplicate-item denial on durable medical equipment.
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →Related appeal guides
- Blue Cross Blue Shield denied as duplicate or overlapping therapy of 17ohp Compounded
- Blue Cross Blue Shield denied as duplicate or overlapping therapy of AAT Augmentation
- Blue Cross Blue Shield denied as duplicate or overlapping therapy of Amphetamine Stimulant Prodrug
- Blue Cross Blue Shield denied as duplicate or overlapping therapy of Anti Cd 20 Ocrevus